{"entity":{"id":"nct06174987","kind":"trial","name":"A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)","aka":[],"tldr":"A phase 3 trial of Trastuzumab deruxtecan in metastatic cancer, run by Daiichi Sankyo, now recruiting.","summary":"A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) is a phase 3 interventional study registered as NCT06174987 by Daiichi Sankyo, with 50 participants planned, started 2024-01-05 and due to reach its primary completion in 2026-08-03. Interventions recorded: T-DXd. Conditions listed: Advanced Cancer, Metastatic Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06174987","url":"https://clinicaltrials.gov/study/NCT06174987"}],"tags":["ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-deruxtecan"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06174987","phase":"3","setting":"A Master Rollover Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)","sponsor":"Daiichi Sankyo","enrolled":50,"outcomes":[]},"route":"/trials/nct06174987/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"trastuzumab-deruxtecan","kind":"drug","name":"Trastuzumab deruxtecan","route":"/drugs/trastuzumab-deruxtecan/"}],"company":[{"id":"daiichi-sankyo","kind":"company","name":"Daiichi Sankyo","route":"/companies/daiichi-sankyo/"}]}}